Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.
Inclusion Criteria:
Exclusion Criteria:
Troy, Michigan 48098, United States
CABA, Buenos Aires 1023, Argentina
CABA, Buenos Aires C1060ABN, Argentina
Ciudad Autonoma de Buenos Aires, Buenos Aires C1405BUB, Argentina
Ciudad Autónoma de Buenos Aires, Buenos Aires C1056, Argentina
Suita-shi, Osaka 565-0853, Japan
Chuo-ku, Tokyo 103-0027, Japan
Chuo-ku, Tokyo 103-0028, Japan
Chuo-ku, Tokyo 104-0031, Japan
Mexicali, Estado de Baja California 21200, Mexico
Mexico City, Mexico City 11650, Mexico
Culiacán, Sinaloa 80230, Mexico
Saint Petersburg, Sankt-Peterburg 196601, Russia
Taipei City, Taipei 10002, Taiwan